Clinical & Laboratory Immunology
American Board of Allergy & Immunology
Rheumatology
American Board of Internal Medicine
MD, New York University
Residency, Internal Medicine
University of Chicago Hospitals
Residency, Internal Medicine
Bellevue Hospital Center
Residency, Internal Medicine
New York University Medical Center
Residency, Internal Medicine
New York University School of Medicine
Fellowship, Rheumatology
New York University Medical Center
Fellowship, Allergy & Immunology
New York University Medical Center
English, French
2009
Best Doctors
New York Magazine
Peter Gorevic is Professor of Medicine of Chief of the Division of Rheumatology. In ongoing studies, he is examining the pathogenesis of the various forms of amyloid disease, with emphasis on those that are concomitant with the aging process in man, including Alzheimer's disease, and articular amyloid often associated with osteoarthritis. Other studies focus on Dialysis Amyloidosis, a major cause of arthropathy and spondyloarthropathy in patients maintained by long-term dialysis. A variety of agents have been proposed to be generic therapeutics for the treatment of the amyloid diseases, including small peptides corresponding to the subsequences of amyloidogenic proteins, monoclonal antibodies, and compounds that interfere with binding to relevant confactors. A transgenic animal model for dialysis amyloidosis, and an in vitro model for cerebrovascular amyloid are under development, each of which will be used for the development of novel diagnostics and to test therapeutics. Other ongoing studies focus on the autoimmune phenomena and clinical deseases that are extrahepatic manifestations of hepatitis C Virus (HCU), and the potential use of this virus to provoke lymphoproliferative diseases such as non-Hodgkin's lymphoma. In particular, the localization of HCU to cryoprecipitable immune complexes is being examined, as well as the effect of biological such as interferon alpha in inhibitig viral replication and B cell proliferation. These studies are funded by NIH-NIDDK, NIH-NINDS, and the Alzheimer's Association.
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
The purpose of this study is to evaluate the safety and effectiveness of Ledipasvir/Sofosbuvir 90mg/400mg daily in subjects with chronic genotype 1 Hepatitis C virus (HCV) infection with symptoms of cryoglobulinemia: joint pain, vasculitis (inflammation of blood vessels), glomeru...
A Phase 3 Multicenter Multinational Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy – FAP) (APOLLO)
The purpose of this study is to collect information about how patients with FAP respond to the study drug Patisiran (ALN-TTR02) over 18 months. In this study the study drug subjects receive either the active investigational drug patisiran (at a dose of 0.3 mg/kg) or placebo (a du...
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP)
The purpose of this study is to determine whether longer treatment with ISIS 420915 (the study drug) is safe and effective in helping people with mild or moderate Familial Amyloid Polyneuropathy (FAP).
This is a multicenter open-label study. Eligible patients who have s...
A Multicenter International Phase 3 Double-Blind Placebo-Controlled Randomized Study to Evaluate the Efficacy Safety and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)
The purpose of this study is to compare the effects over 30 months of the study drug tafamidis meglumine (hereafter called tafamidis) at two different doses (20 mg and 80 mg) with placebo to find out which is better for treating Transthyretin Cardiomyopathy (TTR-CM). Subject...
A Phase 2/3 Randomized Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy
The drug being researched is called ISIS 420915. ISIS 420915 is an investigational drug. An "investigational drug" is one that is not approved by regulatory authorities such as "US Food and Drug Administration (FDA)". The drug is not for sale in any country. The purpose of this s...
Wilson L, Reichler B, Gorevic P. Cyoglobulinemic and noncryoglobulinemic neuropathy in chronic hepatitis C virus (HCV) infection [abstract]. Mt Sinai J Med. 2000; 68:. 153-3.
Gorevic PD, Galankis DK. Cryoglobulinemia, Cryofibrinogens and Pyroglobulinemia. In: Detrick B , Hamilton RG, Folds JD, editors. Manual of Molecular and Clinical Laboratory Immunology. 7th ASM Press; 2006. pp101-113.
Dember L, Hawkins P, Hazenberg BP C, Gorevic PD. Eprodisate for the Treatment of AA Amyloidosis. New Eng J Med;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Gorevic during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.